Cancer Therapy Advisor Staff

Researchers are conducting a phase 2 study to compare trastuzumab-based treatment regimens in patients with advanced HER2+ breast cancer.

Researchers are conducting a phase 1 study to test capecitabine in combination with cemiplimab in patients with HR+ metastatic breast cancer.

Researchers are conducting a phase 2 study to determine if ctDNA can be used to guide treatment in patients with ER+, HER2- breast cancer at high risk of recurrence.

Researchers are conducting a phase 2 study to test the safety and efficacy of durvalumab in combination with trastuzumab and pertuzumab for HER2-enriched breast cancer.

Researchers are conducting a phase 2 study to determine the safety and efficacy of talazoparib for patients with BRCA1/2-mutated metastatic breast cancer.

Researchers are conducting a phase 1 study to test dendritic cell vaccination in combination with standard chemotherapy in patients with triple-negative breast cancer or hormone receptor-low breast cancer.

Researchers are conducting a phase 2 trial to evaluate combination pembrolizumab and olaparib in BRCA-mutated/HDR-defect advanced breast cancer.

Researchers are conducting a phase 2 trial to test niraparib, dostarlimab, and radiotherapy in patients with metastatic triple-negative breast cancer.